Welcome to LookChem.com Sign In|Join Free

CAS

  • or

56824-87-4

Post Buying Request

56824-87-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

56824-87-4 Usage

General Description

Ethyl 4-chloro-6-methylquinoline-3-carboxylate is a chemical compound belonging to the class of organic compounds known as quinolines and derivatives. Quinolines are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyridine ring to form quinoline. The Ethyl 4-chloro-6-methylquinoline-3-carboxylate compound specifically contains a chloro group, which is a covalently bonded atom of chlorine with valence electron deficiencies, along with an ethyl group and a carboxylate group. It also showed potential as starting material for synthesizing other complex chemical compounds. Ethyl 4-chloro-6-methylquinoline-3-carboxylate is generally insoluble in water, however, it can be soluble in organic solvents. Proper handling and storage are crucial, as it may pose health risks if improperly handled.

Check Digit Verification of cas no

The CAS Registry Mumber 56824-87-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,8,2 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 56824-87:
(7*5)+(6*6)+(5*8)+(4*2)+(3*4)+(2*8)+(1*7)=154
154 % 10 = 4
So 56824-87-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H12ClNO2/c1-3-17-13(16)10-7-15-11-5-4-8(2)6-9(11)12(10)14/h4-7H,3H2,1-2H3

56824-87-4 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H50505)  Ethyl 4-chloro-6-methylquinoline-3-carboxylate   

  • 56824-87-4

  • 250mg

  • 515.0CNY

  • Detail
  • Alfa Aesar

  • (H50505)  Ethyl 4-chloro-6-methylquinoline-3-carboxylate   

  • 56824-87-4

  • 1g

  • 1874.0CNY

  • Detail

56824-87-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl 4-chloro-6-methylquinoline-3-carboxylate

1.2 Other means of identification

Product number -
Other names Ethyl 4-chloro-6-methyl-quinoline-3-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:56824-87-4 SDS

56824-87-4Relevant articles and documents

Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights

Abdelgawad, Mohamed A.,Al-Sanea, Mohammad M.,Alharbi, Khalid S.,Ali Farahat, Ibrahim,Alzarea, Abdulaziz I.,Alzarea, Sami I.,Bakr, Rania B,El Kerdawy, Ahmed M.,Eldehna, Wagdy M.,Elkamhawy, Ahmed,Elshemy, Heba A. H.,Joo Roh, Eun,Lee, Kyeong,Paik, Sora,Syed Nasir Abbas, Bukhari

, (2020/05/08)

Aurora kinases (AURKs) were identified as promising druggable targets for targeted cancer therapy. Aiming at the development of novel chemotype of dual AURKA/B inhibitors, herein we report the design and synthesis of three series of 4-anilinoquinoline derivatives bearing a sulfonamide moiety (5a-d, 9a-d and 11a-d). The percent inhibition of AURKA/B was determined for all target quinolines, then compounds showed more than 50percent inhibition on either of the enzymes, were evaluated further for their IC50 on the corresponding enzyme. In particular, compound 9d displayed potent AURKA/B inhibitory activities with IC50 of 0.93 and 0.09 μM, respectively. Also, 9d emerged as the most efficient anti-proliferative analogue in the US-NCI anticancer assay toward the NCI 60 cell lines panel, with broad spectrum activity against different cell lines from diverse cancer subpanels. Docking studies, confirmed that, the sulfonamide SO2 oxygen was involved in a hydrogen bond with Lys162 and Lys122 in AURKA and AURKB, respectively, whereas, the sulfonamide NH could catch hydrogen bond interaction with the surrounding amino acid residues Lys141, Glu260, and Asn261 in AURKA and Lys101, Glu177, and Asp234 in AURKB. Furthermore, N1 nitrogen of the quinoline scaffold formed an essential hydrogen bond with the hinge region key amino acids Ala213 and Ala173 in AURKA and AURKB, respectively.

Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors

Al-Sanea, Mohammad M.,Elkamhawy, Ahmed,Paik, Sora,Bua, Silvia,Ha Lee, So,Abdelgawad, Mohamed A.,Roh, Eun Joo,Eldehna, Wagdy M.,Supuran, Claudiu T.

, p. 1457 - 1464 (2019/08/26)

Carbonic anhydrases (CAs, EC 4.2.1.1) are crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate moieties. The newly synthesised compounds were in vitro evaluated as inhibitors of the cytosolic human (h) isoforms hCA I and II. Both isoforms hCA I and II were inhibited by the quinolines reported here in variable degrees: hCA I was inhibited with KIs in the range of 0.966–9.091 μM, whereas hCA II in the range of 0.083–3.594 μM. The primary 7-chloro-6-flouro substituted sulphfonamide derivative 6e (KI = 0.083 μM) proved to be the most active quinoline in inhibiting hCA II, whereas, its secondary sulfonamide analog failed to inhibit the hCA II up to 10 μM, confirming the crucial role of the primary sulphfonamide group, as a zinc-binding group for CA inhibitory activity.

Tetracyclic lactam compound, preparation method and application thereof

-

Paragraph 0163, (2018/10/19)

The invention relates to a tetracyclic lactam compound, or a tautomer, a stereisomer, racemate, a non-equivalent mixture of an enantiomer, a geometrical isomer, a solvate, medically acceptable salt orprodrug thereof, and a drug combination containing the same. The invention further discloses application of the tetracyclic lactam compound or the drug combination serving as drugs, particularly as antibacterial, antiviral and antiparasitic drugs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 56824-87-4